Investigators developed a droplet digital PCR assay targeting driver mutations and found that changes in circulating DNA were correlated with response to radiation.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
In PNAS this week: targeting recurrent IDH1 and IDH2 mutations in gliomas, silkworms genetically modified to produce spider silk, and more.
Patients whose tumors had methylated MGMT promoters were more likely to survive than those that did not after combination treatment with radiotherapy and temozolomide.
A modified poliovirus could be a promising treatment for brain cancer, according to NPR.
Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.
In Genome Biology this week: tumor-associated macrophage patterns in glioma, systems epigenomics algorithm, and more.
Many molecularly distinct subgroups emerged from a meta-analysis bringing together more than 1,000 high-grade glioma or diffuse intrinsic pontine glioma cases.
Oncoscape, an open-source data tool developed at Fred Hutchinson Cancer Research Center, will soon be able to produce 3D exome visualizations on commercial VR headsets.
A multi-region analysis of medulloblastoma and other tumor types highlighted the dramatic somatic alteration differences that can crop up within a single tumor.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.